The primary endpoint was the proportion of participants achieving EASI-75 at Week 16.
In the full analysis set, 51 of 108 participants (47.2%) on VRN-118 200 mg achieved EASI-75, compared with 10 of 54 (18.5%) on placebo.
The difference was 28.7 percentage points (95% CI 14.7 to 42.7; p<0.001), from the Cochran–Mantel–Haenszel test stratified by baseline severity.
Waiting for a yes
Upload section 11.4.1 to SharePoint › CSR › VRN-118-201
A. Ferri, medical writing lead